Analysis of COVID-19 Crisis-driven Growth Opportunities in Alpha Mannosidosis Market

Transparency Market Research (TMR) has published a new report titled, ‘Alpha mannosidosis Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global alpha mannosidosis market was valued at US$ 7.6 Mn in 2018 and is projected to expand at a CAGR of 9.9% from 2019 to 2027.

Overview

Alpha-mannosidosis is a rare genetic disease caused by the deficiency of an enzyme called alpha-mannosidase
It is hereditary autosomal recessive disorder and both chromosome copies carry mutations in the alpha-mannosidase gene MAN2B1
Alpha-mannosidase breaks down oligosaccharides. The absence of enzyme leads to accumulation of oligosaccharides inside the cell, resulting in damage of tissues and organs and leading to cell death
Treatment of alpha-mannosidosis is suggestive and supportive. Therapy is focused at preventing and treating the difficulties of the disorder
Some of the therapies include Bone Marrow Transplant (BMT), Peripheral blood stem cell transplantation (PBSCT), Enzyme replacement therapy (ERT), Gene Therapy and others

Patent-cliff To Drive Rare Disease Market to Drive Market

Orphan drugs are used to treat rare diseases. Alpha-mannosidosis is a rare genetic disorder. Medications for orphan diseases are very expensive ranging from US $ 2,00,000 to US $ 4,00,000. The potential for big profits on expensive drugs is a major incentive for drug companies
Moreover, patents on several big-name drugs are soon expected to expire, opening the door to generic drug competition and reducing drug company returns. This patent cliff makes the rare-disease market more attractive for investment by the companies.

Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2501

Bone Marrow Transplant Segment to Dominate Market

Based on treatment type, the global alpha mannosidosis market has been divided into bone marrow transplant (BMT) and enzyme replacement therapy (ERT). A bone marrow or cord blood transplant is a process to replace unhealthy bone marrow with healthy bone marrow. Bone marrow transplantation (BMT) has been shown to lead to balance of neurological function in some lysosomal storage diseases. BMT has been traditionally used to treat patients suffering from Alpha Mannosidosis, however, he high morbidity and mortality associated with the procedure has limited its use
The major limitation of BMT is that only a very small number of cells of bone marrow origin migrate to the brain and differentiate into CNS resident macrophages (microglia).

Hospitals End-user segment to be Highly Lucrative Segment

In terms of end-user, the global alpha mannosidosis market has been classified into hospitals and specialty clinics.
Hospitals market accounted for majority of the end-user market share in 2017 and the share is continuously expected to increase till 2027
Similarly, the hospitals market is expected to grow at considerable rate during the forecast period with increasing number of treatment procedures performed worldwide
The specialty clinics market are expected to grow at slow pace compared to hospitals market.

Request For Covid19 Impact Analysis – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2501

North America to Dominate Global Market

In terms of region, the global alpha mannosidosis market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global alpha mannosidosis market in 2018, followed by Europe.
North America accounted for major share of the global alpha mannosidosis market in 2018, owing to high prevalence rates.
The prevalence and incidence of Alpha Mannosidosis is quite high in North America, Europe and Asia Pacific. The prevalence is generally unknown but believed to occur in approximately 1 in 10,00,000 people worldwide. It has been described in all ethnic groups.

Buy Now Report : https://www.transparencymarketresearch.com/checkout.php?rep_id=2501&ltype=S

Competitive Landscape

The alpha mannosidosis market currently only one companyhaving their products marketed. However, many companies have their products in the clinical stages that would fuel the market growth. Zymenex is the leading player in the market focusing on R&D to fight genetic diseases.The company has developed Lamazym, a recombinant enzyme indicated for patients with alpha mannosidosis.

The global alpha mannosidosis market has been segmented as follows:

Global Alpha mannosidosis Market, by Treatment Type

Bone Marrow Transplant
Enzyme Replacement Therapy

Global Alpha mannosidosis Market, by Indication

Type I
Type II
Type III

Global Alpha mannosidosis Market, by End-user

Hospitals
Specialty Clinics

Global Alpha mannosidosis Market, by Region

North America

U.S.
Canada

Europe

Germany
U.K.
France
Italy
Spain
Rest of Europe

Asia Pacific

China
India
Japan
Australia & New Zealand
Rest of Asia Pacific

Latin America

Brazil
Mexico
Rest of Latin America

Middle East & Africa

GCC Countries
South Africa
Rest of Middle East & Africa